The co-administration of MPT0E028 and mitogen-activated protein kinase (MEK) inhibitors has synergistic effects in KRAS-mutated and KRAS-wild-type pancreatic cancer cells. This evidence concerns the gene MAP2K7 and pancreatic neoplasm.